Propranolol has been used in combination with Etodolac, a non-steroidal anti-inflammatory drug (NSAID) that acts as a competitive inhibitor of Cyclooxygenase 2 (COX-2), in four different studies as a preoperative combination therapy with propranolol for colorectal, pancreatic, and breast neoplasms. The gene discussed is PTGS2; the disease is breast neoplasm.